vs
MESA LABORATORIES INC（MLAB）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是REGIS CORP的1.1倍（$65.1M vs $57.1M），MESA LABORATORIES INC净利率更高（5.6% vs 0.8%，领先4.8%），REGIS CORP同比增速更快（22.3% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $891.0K），过去两年REGIS CORP的营收复合增速更高（7.8% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
MLAB vs RGS — 直观对比
营收规模更大
MLAB
是对方的1.1倍
$57.1M
营收增速更快
RGS
高出18.6%
3.6%
净利率更高
MLAB
高出4.8%
0.8%
自由现金流更多
MLAB
多$17.1M
$891.0K
两年增速更快
RGS
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $57.1M |
| 净利润 | $3.6M | $456.0K |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | 10.8% |
| 净利率 | 5.6% | 0.8% |
| 营收同比 | 3.6% | 22.3% |
| 净利润同比 | 316.6% | -94.0% |
| 每股收益（稀释后） | $0.65 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRGS
| Q4 25 | $65.1M | $57.1M | ||
| Q3 25 | $60.7M | $59.0M | ||
| Q2 25 | $59.5M | $60.4M | ||
| Q1 25 | $62.1M | $57.0M | ||
| Q4 24 | $62.8M | $46.7M | ||
| Q3 24 | $57.8M | $46.1M | ||
| Q2 24 | $58.2M | $49.4M | ||
| Q1 24 | $58.9M | $49.2M |
净利润MLABRGS
| Q4 25 | $3.6M | $456.0K | ||
| Q3 25 | $2.5M | $1.4M | ||
| Q2 25 | $4.7M | $116.5M | ||
| Q1 25 | $-7.1M | $250.0K | ||
| Q4 24 | $-1.7M | $7.6M | ||
| Q3 24 | $3.4M | $-853.0K | ||
| Q2 24 | $3.4M | $91.2M | ||
| Q1 24 | $-254.6M | $-2.3M |
毛利率MLABRGS
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRGS
| Q4 25 | 12.2% | 10.8% | ||
| Q3 25 | 7.8% | 10.0% | ||
| Q2 25 | 5.1% | 12.1% | ||
| Q1 25 | 2.4% | 8.8% | ||
| Q4 24 | 9.2% | 11.8% | ||
| Q3 24 | 6.1% | 4.6% | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | -460.6% | 8.3% |
净利率MLABRGS
| Q4 25 | 5.6% | 0.8% | ||
| Q3 25 | 4.1% | 2.3% | ||
| Q2 25 | 8.0% | 192.9% | ||
| Q1 25 | -11.4% | 0.4% | ||
| Q4 24 | -2.7% | 16.4% | ||
| Q3 24 | 5.9% | -1.9% | ||
| Q2 24 | 5.8% | 184.7% | ||
| Q1 24 | -432.2% | -4.7% |
每股收益（稀释后）MLABRGS
| Q4 25 | $0.65 | $0.16 | ||
| Q3 25 | $0.45 | $0.49 | ||
| Q2 25 | $0.85 | $43.67 | ||
| Q1 25 | $-1.30 | $0.08 | ||
| Q4 24 | $-0.31 | $2.71 | ||
| Q3 24 | $0.63 | $-0.36 | ||
| Q2 24 | $0.62 | $38.40 | ||
| Q1 24 | $-47.26 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $18.4M |
| 总债务越低越好 | $68.4M | $113.3M |
| 股东权益账面价值 | $186.7M | $188.7M |
| 总资产 | $434.8M | $588.3M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资MLABRGS
| Q4 25 | $29.0M | $18.4M | ||
| Q3 25 | $20.4M | $16.6M | ||
| Q2 25 | $21.3M | $17.0M | ||
| Q1 25 | $27.3M | $13.3M | ||
| Q4 24 | $27.3M | $10.2M | ||
| Q3 24 | $24.3M | $6.3M | ||
| Q2 24 | $28.5M | $10.1M | ||
| Q1 24 | $28.2M | $5.9M |
总债务MLABRGS
| Q4 25 | $68.4M | $113.3M | ||
| Q3 25 | $69.4M | $111.3M | ||
| Q2 25 | $70.3M | $110.8M | ||
| Q1 25 | $71.3M | $112.0M | ||
| Q4 24 | $72.2M | $111.5M | ||
| Q3 24 | $73.1M | $95.2M | ||
| Q2 24 | $74.1M | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益MLABRGS
| Q4 25 | $186.7M | $188.7M | ||
| Q3 25 | $178.5M | $187.6M | ||
| Q2 25 | $172.5M | $185.6M | ||
| Q1 25 | $159.8M | $68.6M | ||
| Q4 24 | $155.2M | $66.7M | ||
| Q3 24 | $161.5M | $56.4M | ||
| Q2 24 | $150.7M | $56.8M | ||
| Q1 24 | $145.4M | $-35.8M |
总资产MLABRGS
| Q4 25 | $434.8M | $588.3M | ||
| Q3 25 | $430.4M | $592.1M | ||
| Q2 25 | $435.7M | $599.0M | ||
| Q1 25 | $433.3M | $511.2M | ||
| Q4 24 | $433.3M | $530.1M | ||
| Q3 24 | $454.1M | $508.9M | ||
| Q2 24 | $440.4M | $530.5M | ||
| Q1 24 | $446.8M | $543.7M |
负债/权益比MLABRGS
| Q4 25 | 0.37× | 0.60× | ||
| Q3 25 | 0.39× | 0.59× | ||
| Q2 25 | 0.41× | 0.60× | ||
| Q1 25 | 0.45× | 1.63× | ||
| Q4 24 | 0.47× | 1.67× | ||
| Q3 24 | 0.45× | 1.69× | ||
| Q2 24 | 0.49× | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $891.0K |
| 自由现金流率自由现金流/营收 | 27.7% | 1.6% |
| 资本支出强度资本支出/营收 | 1.1% | 1.4% |
| 现金转化率经营现金流/净利润 | 5.17× | 3.65× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $14.9M |
8季度趋势，按日历期对齐
经营现金流MLABRGS
| Q4 25 | $18.8M | $1.7M | ||
| Q3 25 | $8.2M | $2.3M | ||
| Q2 25 | $1.9M | $6.8M | ||
| Q1 25 | $12.7M | $6.2M | ||
| Q4 24 | $18.1M | $2.1M | ||
| Q3 24 | $5.3M | $-1.3M | ||
| Q2 24 | $10.7M | $5.1M | ||
| Q1 24 | $12.9M | $-277.0K |
自由现金流MLABRGS
| Q4 25 | $18.0M | $891.0K | ||
| Q3 25 | $7.1M | $1.9M | ||
| Q2 25 | $884.0K | $6.2M | ||
| Q1 25 | $11.9M | $5.9M | ||
| Q4 24 | $17.3M | $1.7M | ||
| Q3 24 | $3.5M | $-1.4M | ||
| Q2 24 | $9.9M | $5.1M | ||
| Q1 24 | $12.3M | $-326.0K |
自由现金流率MLABRGS
| Q4 25 | 27.7% | 1.6% | ||
| Q3 25 | 11.7% | 3.2% | ||
| Q2 25 | 1.5% | 10.3% | ||
| Q1 25 | 19.2% | 10.3% | ||
| Q4 24 | 27.6% | 3.6% | ||
| Q3 24 | 6.0% | -3.0% | ||
| Q2 24 | 16.9% | 10.3% | ||
| Q1 24 | 21.0% | -0.7% |
资本支出强度MLABRGS
| Q4 25 | 1.1% | 1.4% | ||
| Q3 25 | 1.8% | 0.7% | ||
| Q2 25 | 1.7% | 0.9% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 1.3% | 0.9% | ||
| Q3 24 | 3.1% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 0.9% | 0.1% |
现金转化率MLABRGS
| Q4 25 | 5.17× | 3.65× | ||
| Q3 25 | 3.32× | 1.68× | ||
| Q2 25 | 0.40× | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
